{"entity":{"id":"nct07697586","kind":"trial","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of SKB264+SKB118 in non-small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","summary":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07697586 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 206 participants planned, started 2026-08-07 and due to reach its primary completion in 2028-08. Interventions recorded: SKB264+SKB118.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07697586","url":"https://clinicaltrials.gov/study/NCT07697586"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07697586","phase":"2","setting":"A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":206,"outcomes":[]},"route":"/trials/nct07697586/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}